Prof. Dr. Jalid Sehouli is a renowned gynecologist and oncologist currently practicing at Charité University Hospital in Berlin, one of Europe's leading medical institutions. As a top gynecologic oncologist in Germany, Prof. Sehouli is widely recognized for his remarkable career that blends clinical excellence with academic distinction. Of German and Moroccan origin, he completed his medical studies at Humboldt University and earned his doctorate from Charité University Hospital in Gynecology and Obstetrics. Since 2007, he has held senior leadership positions at Charité, culminating in his current role as Director of the Department of Gynecology at Charité Campus Benjamin Franklin. His influence extends beyond the clinic; Prof. Sehouli is the president of PARSGO, head of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), and a key member of global oncological societies. With over 350 scientific publications and more than 50 book contributions, his work has helped shape the global discourse in gynecologic oncology. His dedication and visionary leadership make him a leading gynecologist in Germany and a globally recognized figure in women's health.
Prof. Dr. Jalid Sehouli's expertise lies in the surgical and medical management of complex gynecological cancers, including ovarian, uterine, cervical cancer, and endometriosis. He is one of the best gynecologic oncologists in Germany, offering advanced, minimally invasive procedures using both robotic and laparoscopic techniques. Prof. Sehouli leads the Competence Center for Ovarian Cancer at Charité and plays a vital role in the international biobank for ovarian cancer research. His medical training was enriched with a specialization in gynecological oncology in 2006, further solidifying his reputation as a top surgical expert in female cancer treatment. His approach combines advanced techniques with a strong academic foundation, which is reflected in his high success rates and innovative treatment protocols. Prof. Sehouli’s affiliation with top international bodies, such as ESGO and ASCO, ensures he remains at the forefront of emerging cancer therapies. Whether managing routine cases or complex oncologic surgeries, he stands as a popular and trusted name among cancer patients globally, drawing medical tourists from around the world.